Needle-free vaccines Jurata is actively developing needle-free mRNA vaccines and wafer-like film delivery systems, presenting a clear sales lever for partnerships or licensing in alternative administration platforms and room-temperature storage solutions.

Room-temperature storage The focus on eliminating cold storage and enabling shelf-stable formulations opens opportunities with global immunization programs, humanitarian aid organizations, and supply chain partners seeking cost reductions and expanded access in low-resource settings.

Strategic partnerships Collaborations with CEPI and Gates-funded initiatives indicate a readiness to engage with public-private consortia, creating avenues for co-development deals, grant-funded programs, and joint go-to-market strategies.

Early-stage funding With seed funding and a reported revenue trajectory, there is potential to position Jurata for follow-on investment discussions, strategic alliances, or contract manufacturing opportunities as their technology matures.

Small team agility A lean team in biotechnology can be a selling point for outsourcing partnerships, contract development, and scalable manufacturing collaborations as Jurata seeks to accelerate clinical progress and commercialization.